Tricyclic heterocyclic derivatives

A tricyclic heterocyclic derivative according to Formula I

• wherein
• m is 1 or 2;
• n is 0 or 1;
• R1 is H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-2alkyl, C1-2alkyloxyC1-2alkyl or C6-10arylC1-2alkyl, said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-2alkyl, C1-2alkyloxyC1-2alkyl and C6-10arylC1-2alkyl each being optionally substituted with one or more halogens;
• R2 is H, C1-4alkyl, C3-5cycloalkyl or C3-5cycloalkylC1-2alkyl said C1-4alkyl, C3-5cycloalkyl and C3-5cycloalkylC1-2alkyl each being optionally substituted with one or more halogens;
• R3 is C1-4alkyl, hydroxyC1-2alkyl or C1-2alkyloxyC1-2alkyl said C1-4alkyl and C1-2alkyloxyC1-2alkyl each being optionally substituted with one or more halogens;
• L1 is C═O or CR4R5;
• L2 is CR4′R5′
• R4, R4′, R5 and R5′ are each independently H, F, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, hydroxy, C1-4alkyloxy, C1-2alkyloxyC1-2alkyl, C3-5cycloalkyl or C3-5cycloalkylC1-2alkyl said C1-4alkyl, C3-5cycloalkyl and C3-5cycloalkylC1-2alkyl each being optionally substituted with one or more halogens or
• one of R4 and R4′ together with one of R5 and R5′ along with the atoms to which they are bonded form a 3-6 membered ring optionally comprising a heteroatom selected from O, S and NR4″, wherein R4″ is H, C1-4alkyl, COC1-4alkyl or SO2C1-4alkyl.
• Y1 is N or CR6;
• Y2 is N or CR7;
• Y3 is N or CR8;
• Y4 is N or CR9 with the proviso that no more than two of Y1-Y4 can be N simultaneously;
• R6, R7 and R8 are each independently selected from H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-2alkyl, C1-6alkyloxy, SC1-6alkyl, SOC1-6alkyl, SO2C1-6alkyl, NR10R11, CO2R12, C6-10aryl, C6-10arylC1-2alkyloxy, CN, halogen and a 5-6 membered heteroaryl ring system comprising 1-2 heteroatoms independently selected from N, O and S, wherein said C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-2alkyl and C1-6alkyloxy are each optionally substituted with one or more halogens and wherein said C6-10aryl, 5-6 membered heteroaryl ring system comprising 1-2 heteroatoms independently selected from N, O and S and C6-10arylC1-2alkyloxy are optionally independently substituted with one or more substitutents independently selected from methyl and halogen or;
• R6 and R7 or R7 and R8 together with the atoms to which they are bonded form a 5-7
• membered unsaturated ring optionally comprising 1-2 heteroatoms selected from NR6′,
• O and S and optionally substituted with methyl or halogen, wherein R6′ is H or C1-4alkyl;
• R9 is H, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, CN or halogen said C1-6alkyl, C3-7cycloalkyl and C1-6alkyloxy each being optionally substituted with one or more halogens with the proviso that R6-R9 cannot simultaneously be H;
• R10 and R11 are each independently H or C1-6alkyl and
• R12 is C1-6alkyl;
• or a pharmaceutically acceptable salt thereof.